Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Sarcoidosis, Pulmonary
Interventions: Atorvastatin, Placebo Oral Tablet; Drug · Other
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Lymphoma
Interventions: PARASYM neuromodulation device; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Tulsa, Oklahoma

Conditions: Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Interventions: Calmangafodipir (2 µmol/kg), Calmangafodipir (5 µmol/kg), Placebo; Drug
Lead sponsor: Egetis Therapeutics AB (publ); Industry
Eligibility: 18 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Fresno, California • Orange City, Florida • Wichita, Kansas + 8 more

Conditions: Penile Cancer, Erectile Dysfunction, Radical Prostatectomy
Interventions: Placebo QHS and sildenafil and questionnaires, Sildenafil and questionnaire, Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Respiratory Papillomatosis
Interventions: celebrex (celecoxib), placebo; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 2 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Iowa City, Iowa + 4 more

Conditions: Healthy
Interventions: PF-06669571; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Asthma
Interventions: E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 Placebo, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg, epinephrine inhalation aerosol, CFC propelled, E004 (epinephrine inhalation aerosol), 160 mcg; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 2
States / cities: San Jose, California • Stockton, California

Conditions: Smoking Cessation
Interventions: Propranolol, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small Cell Lung Cancer
Interventions: bevacizumab, placebo, erlotinib HCl; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 177
States / cities: Mobile, Alabama • Fort Smith, Arizona • Scottsdale, Arizona + 160 more

Conditions: Autism Spectrum Disorder
Interventions: Oral cannabidiol 100mg/mL, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 5 Years to 17 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Certolizumab Pegol, Etanercept, Placebo; Biological · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 19
States / cities: Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more

Conditions: Squamous Non Small Cell Lung Cancer
Interventions: HLX10, carboplatin and nab paclitaxel, Placebo; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Pharyngitis
Interventions: placebo, flurbiprofen, acetaminophen 650mg; Drug
Lead sponsor: Reckitt Benckiser LLC; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin; Drug
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 2 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Body Dysmorphic Disorder, Obsessive-compulsive Disorder
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer, Erectile Dysfunction
Interventions: sildenafil citrate and questionaires, placebo tablets and questionaires; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Male only
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: COVID-19
Interventions: Clazakizumab, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 16
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more

Conditions: Cancer
Interventions: glutamine, placebo; Dietary Supplement · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 17
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 14 more

Conditions: Epilepsy, Sleep
Interventions: Lemborexant, Placebo; Drug
Lead sponsor: University of Manitoba; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 2 Diabetes
Interventions: AZD0186, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Glendale, California

Conditions: Safety, Tolerability, Pharmacokinetics, Healthy Participants
Interventions: AZD7503, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Stroke, Acute
Interventions: Valsartan; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Pain
Interventions: SUZ, HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,075 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 21
States / cities: Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 18 more

Search by objective public record fields.

Atorvastatin to Treat Pulmonary Sarcoidosis

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions

Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.

Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Oxytocin Administration in BDD and OCD

Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer

Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer

Lemborexant Treatment of Insomnia Linked to Epilepsy

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

Blood Pressure Lowering in Acute Stroke Trial

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy